Infantile Hemangioma and Updated Recommended Treatment

  • Maria João Silva Grupo Português de Dermatologia Pediátrica, Serviço de Dermatologia, Hospital Distrital de Santarém E.P.E, Portugal
  • Jorge Palácios Unidade de Cirurgia Pediátrica, Centro Hospitalar de Setúbal, E.P.E., Portugal e Hospital do Espírito Santo de Évora, E.P.E., Portugal
  • Mónica Rebelo Unidade de Cardiologia Pediátrica do Departamento de Pediatria, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, E.P.E, Centro Académico de Medicina de Lisboa, Portugal
  • Erica Torres Unidade de Cuidados Intensivos Pediátricos, Departamento de Pediatria, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, E.P.E, Centro Académico de Medicina de Lisboa, Portugal
Keywords: Hemangioma/surgery, Hemangioma/therapy, Lasers, Propranolol


Infantile hemangioma is a benign vascular tumor that frequently occurs at pediatric age, normally at a rate of 2% to 12% in Caucasian newborn babies, particularly in females. The International Society for The Study of Vascular Anomalies has divided these anomalies into two categories: vascular tumors and vascular malformations, including infantile hemangioma among benign vascular tumors. Clinical evolution is characteristic, and consists of a proliferative phase and a spontaneous involution phase. Diagnosis is usually clinical, but sometimes other diagnostic procedures may eventually be necessary. The majority of infantile hemangioma has a favorable outcome and spontaneous resolution. However, in some cases there are local or systemic complications, with the need for additional therapeutic intervention in case of vital, functional or esthetic risks. Oral propranolol is the current treatment of choice for infantile hemangioma, being the only treatment internationally approved for this indication. It should be started as early as possible to maximize efficacy and avoid potential complications. Other therapeutic options can be considered as a second choice, such as oral, topical or intralesional corticosteroids, topical beta-blockers, pulsed-dye laser or surgery.


Download data is not yet available.


Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Diagnosis and Management of Infantile Hemangioma: Executive Summary. Pediatrics. 2015;136(4):786-791. doi:10.1542/peds.2015-2482

Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;6736(16):1-10. doi:10.1016/S0140-6736(16)00645-0

Passas MA, Teixeira M. Hemangioma da Infância. Nascer e Crescer. 2016;25(2):83-89.

Paller AS, Mancini AJ. Vascular Disorders of Infancy and Childhood. In: Clinical Pediatric Dermatology. 5th ed. Elsevier; 2016:279-316.

Haggstrom A, Garzon M. Infantile Hemangiomas. In: Dermatology. 4th ed. Elsevier; 2017:1786-1804. [homepage na internet]. International Society for the Study of Vascular Anomalies © 2014. Accessed January 3, 2018.

Drolet BA, Frieden IJ. Characteristics of Infantile Hemangiomas as Clues to Pathogenesis. Arch Dermatol. 2010;146(11):1295-1299. doi:10.1001/archdermatol.2010.1295

Chen TS, Eichenfield LF, Friedlander SF. Infantile Hemangiomas: An Update on Pathogenesis and Therapy. Pediatrics. 2013;131(1):99-108. doi:10.1542/peds.2012-1128

North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol. 2001;137(5):559-570.

Haggstrom AN, Lammer EJ, Schneider RA, Marcucio R, Frieden IJ. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics. 2006;117(3):698-703. doi:10.1542/peds.2005-1092

Bauland CG, Lüning TH, Smit JM, Zeebregts CJ, Spauwen PHM. Untreated Hemangiomas: Growth Pattern and Residual Lesions. Plast Reconstr Surg. 2011;127(4):1643-1648. doi:10.1097/PRS.0b013e318208d2ac

Haggstrom AN, Beaumont JL, Lai J-S, et al. Measuring the Severity of Infantile Hemangiomas. Arch Dermatol. 2012;148(2):197-202. doi:10.1001/archdermatol.2011.926

Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855-865. doi:10.1007/s00431-015-2570-0

Leaute-Labreze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics. 2016;138(4):e20160353-e20160353. doi:10.1542/peds.2016-0353

Blei F, McElhinney DB, Guarini A, Presti S. Cardiac Screening in Infants with Infantile Hemangiomas before Propranolol Treatment. Pediatr Dermatol. 2014;31(4):465-470. doi:10.1111/pde.12344

Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. N Engl J Med. 2015;372(8):735-746. doi:10.1056/NEJMoa1404710

Laranjo S, Costa G, Paramés F, et al. The role of propranolol in the treatment of infantile hemangioma. Rev Port Cardiol. 2014;33(5):289-295. doi:10.1016/j.repc.2013.10.018

Raphael MF, Breugem CC, Vlasveld FAE, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas? J Am Acad Dermatol. 2015;72(3):465-472. doi:10.1016/j.jaad.2014.12.019

Jacks SK, Kertesz NJ, Witman PM, Fernandez Faith E. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas. J Am Acad Dermatol. 2015;73(2):255-257. doi:10.1016/j.jaad.2015.05.015

Hengst M, Oelert M, Hoeger PH. Blood Pressure Monitoring During the Induction and Maintenance Period of Propranolol Therapy for Complicated Infantile Hemangiomas: A Prospective Study of 109 Infants. Pediatr Dermatol. 2015;32(6):802-807. doi:10.1111/pde.12681

Petrovic J, Trifunovic B, Vukomanovic G, Topalovic M, Trajkovic G, Parezanović V. Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. J Dermatolog Treat. 2017;28(6):554-558. doi:10.1080/09546634.2016.1277177

Ji Y, Chen S, Xiang B, Yang Y, Qiu L. Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study. Sci Rep. 2017;7(1):1503. doi:10.1038/s41598-017-01321-2

Carvalho S, Machado S, Selores M. Hemangioma infantil e propranolol oral: recomendações atuais TT - Infant hemangioma and oral propranolol current recommendations. Nascer e Crescer. 2016;25(3):154-158.

Baselga Torres E, Bernabéu Wittel J, van Esso Arbolave DL, et al. Spanish consensus on infantile haemangioma. An Pediatría (English Ed. 2016;85(5):256-265. doi:10.1016/j.anpede.2015.10.017 [homepage da internet]. European Medicines Agency: EMA/111354/2014 - Resumo do Relatório Público Europeu de Avaliação (EPAR) de 2014 relativo ao Hemangiol. Accessed January 3, 2018.

Weibel L, Barysch MJ, Scheer HS, et al. Topical Timolol for Infantile Hemangiomas: Evidence for Efficacy and Degree of Systemic Absorption. Pediatr Dermatol. 2016;33(2):184-190. doi:10.1111/pde.12767

Puttgen K, Lucky A, Adams D, et al. Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics. 2016;138(3):e20160355-e20160355. doi:10.1542/peds.2016-0355

Batta K, Goodyear HM, Moss C, Williams HC, Hiller L, Waters R. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: Results of a 1-year analysis. Lancet. 2002;360(9332):521-527. doi:10.1016/S0140-6736(02)09741-6

Greene AK. Management of hemangiomas and other vascular tumors. Clin Plast Surg. 2011;38(1):45-63. doi:10.1016/j.cps.2010.08.001

Greene AK, Mulliken JB. Vascular anomalies. In: Plastic Surgery: Volume 1: Principles. 4th ed. Elsevier; 2017:866-887.

Liang MG, Frieden IJ. Infantile and congenital hemangiomas. Semin Pediatr Surg. 2014;23(4):162-167. doi:10.1053/j.sempedsurg.2014.06.017

Dementieva N, Jones S. The treatment of problematic hemangiomas in children with propranolol and 940 nm diode laser. J Pediatr Surg. 2016;51(5):863-868. doi:10.1016/j.jpedsurg.2016.02.038

Coulie J, Coyette M, Moniotte S, Bataille A-C, Boon LM. Has Propranolol Eradicated the Need for Surgery in the Management of Infantile Hemangioma? Plast Reconstr Surg. 2015;136(4 Suppl):154. doi:10.1097/01.prs.0000472478.09496.0d

Greene AK. Infantile Hemangioma. In: Operative Management of Vascular Anomalies. 1st ed. Thieme; 2017:25-64. doi:10.1055/b-0037-145005

Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile Hemangioma. Plast Reconstr Surg. 2012;130(3):619-624. doi:10.1097/PRS.0b013e31825dc129

Menapace D, Mitkov M, Towbin R, Hogeling M. The changing face of complicated infantile hemangioma treatment. Pediatr Radiol. 2016;46(11):1494-1506. doi:10.1007/s00247-016-3643-6

How to Cite
Silva, M. J., Palácios, J., Rebelo, M., & Torres, E. (2019). Infantile Hemangioma and Updated Recommended Treatment. Journal of the Portuguese Society of Dermatology and Venereology, 77(1), 39-46.
Review Articles